Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALNY Alnylam Pharmaceuticals

Market Closed 08-14 16:00:00 EDT

228.65

+1.53

+0.67%

盘后224.29

-4.36-1.91%

19:53 EDT

High228.98	Low220.23	Vol1.53M
Open223.52	D1 Closing227.12	Amplitude3.85%
Mkt Cap30.51B	Tradable Cap30.45B	Total Shares133.43M
T/O345.73M	T/O Rate1.15%	Tradable Shares133.16M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"Alnylam Pharmaceuticals","latestPrice":228.65,"timestamp":1786737600000,"preClose":227.12,"halted":0,"volume":1525934,"hourTrading":{"tag":"盘后","latestPrice":224.293,"preClose":228.65,"latestTime":"19:53 EDT","volume":28089,"amount":6421905.448,"timestamp":1786751625819,"change":-4.357,"changeRate":-0.019055,"amplitude":0.019711},"delay":0,"changeRate":0.006736526946107789,"floatShares":133157589,"shares":133427910,"eps":5.619342,"marketStatus":"Market Closed","change":1.53,"latestTime":"08-14 16:00:00 EDT","open":223.52,"high":228.98,"low":220.23,"amount":345728119.69879997,"amplitude":0.038526,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":5.619342,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":227.12,"preHourTrading":{"tag":"盘前","latestPrice":223.51,"preClose":227.12,"latestTime":"09:29 EDT","volume":1931,"amount":433559.14601,"timestamp":1786714199999,"change":-3.61,"changeRate":-0.015895,"amplitude":0.027485},"postHourTrading":{"tag":"盘后","latestPrice":224.293,"preClose":228.65,"latestTime":"19:53 EDT","volume":28089,"amount":6421905.448,"timestamp":1786751625819,"change":-4.357,"changeRate":-0.019055,"amplitude":0.019711},"volumeRatio":0.997377033230803,"impliedVol":0.3765,"impliedVolPercentile":0.1195},"requestUrl":"/m/hq/s/ALNY/wiki","defaultTab":"wiki","newsList":[{"id":"2659205110","title":"Alnylam Pharma (ALNY) Gets a Hold from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2659205110","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659205110?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:55","pubTimestamp":1786701337,"startTime":"0","endTime":"0","summary":"In a report released today, from Wells Fargo maintained a Hold rating on Alnylam Pharma, with a price target of $256.00. In addition to Wells Fargo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alnylam-pharma-alny-gets-a-hold-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alnylam-pharma-alny-gets-a-hold-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4559","LU0130102774.USD","LU1791807156.HKD","IYF","PGF","LU0072461881.USD","LU0417517546.SGD","IE000M9KFDE8.USD","PBE","LU0130517989.USD","LU0251142724.SGD","LU0320765489.SGD","BK4207","LU0868494617.USD","LU1201861249.SGD","LU0128525689.USD","TFNS","GNMX","LU0310800965.SGD","BK4548","KBWB","LU0106831901.USD","LU0267386448.USD","FTXO","LU1894683348.USD","LU0256863811.USD","LU2361044865.SGD","LU0477156953.USD","ALNY","LU0310799852.SGD","LU2361044949.HKD","LU1280957306.USD","LU0787776722.HKD","BK4501","BK4582","LU1267930490.SGD","LU2461242641.AUD","LU1506573853.SGD","LU0942090050.USD","LU0048573561.USD","IE00B19Z3B42.SGD","LU0070302665.USD","LU0114720955.EUR","LU0882574055.USD","LU0128525929.USD","LU1074936037.SGD","IE00B7SZLL34.SGD","BK4585","LU0683600562.USD","LU1069347547.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659113821","title":"U.S. Research Roundup-Cisco, Fox Corp, Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2659113821","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659113821?lang=en_us&edition=fundamental","pubTime":"2026-08-14 16:03","pubTimestamp":1786694628,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Cisco, Fox Corp, TargetAug 14 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cisco, Fox Corp and Ta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL4N44B0HI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGT","AMGN","DISK","FTXO","AEO","KROP","DE","FOXA","AVAH","CSCL","MSGS","ENVX","XYZ","HTFL","IPAR","SMRF","BWXT","IYZ","EAT","LTC","ESS","AEHR","LAZR","TECH","WSM","AMAT","HEI","BURL","NERV","SHOC","LGN","CABA","KTB","MSGE","WDAY","XNTK","CELC","SJM","BJ","AIT","CSCO","SNDG","ALNY","COHC","CTRE","TNUK","COHR","SNDK","CHEF","TPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659245165","title":"Alnylam Pharma (ALNY) Receives a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2659245165","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659245165?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:35","pubTimestamp":1786635358,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Alnylam Pharma today and set a price target of $318.00. According to TipRanks, Matt...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alnylam-pharma-alny-receives-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alnylam-pharma-alny-receives-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","BK4548","ALNY","BK4139","BK4588","LU0114720955.EUR","BK4585","LU0889565916.HKD","GNMX","SF","LU0882574055.USD","PBE","LU0320765992.SGD","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908275","title":"Is Alnylam’s Mixed 2026 Guidance Reset Altering The Investment Case For Alny (ALNY)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908275","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908275?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:26","pubTimestamp":1786537582,"startTime":"0","endTime":"0","summary":"In the second quarter of 2026, Alnylam Pharmaceuticals reported revenue of US$1,290.95 million and net income of US$164.49 million, a shift from a net loss a year earlier, and for the first half of 2026 revenue reached US$2,458.12 million with net income of US$370.49 million. \nOn the same day, the company trimmed its full-year 2026 guidance for total net product revenues while raising expectations for collaboration and royalty income, highlighting a changing balance between its own drug...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/is-alnylams-mixed-2026-guidance-reset-altering-the-investmen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/is-alnylams-mixed-2026-guidance-reset-altering-the-investmen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GNMX","BK4588","LU0320765992.SGD","ALNY","BK4585","LU0114720955.EUR","LU0882574055.USD","BK4139","LU0109394709.USD","LU0889565916.HKD","PBE","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198182185","title":"Movement Alert｜Alnylam Pharmaceuticals Falls 5.04% in Regular Trading, Continued Pressure After Q2 Guidance Cut","url":"https://stock-news.laohu8.com/highlight/detail?id=1198182185","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198182185?lang=en_us&edition=fundamental","pubTime":"2026-08-07 03:12","pubTimestamp":1786043524,"startTime":"0","endTime":"0","summary":"On August 7, Alnylam Pharmaceuticals declined 5.04% in regular trading, trading at $217.44/share, with turnover of $273 million. The stock continues to face selling pressure following its Q2 earnings...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657575666","title":"Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge","url":"https://stock-news.laohu8.com/highlight/detail?id=2657575666","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657575666?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:46","pubTimestamp":1785962781,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Q2 net loss widens on impairment chargeOverviewUS heart disease therapy developer's Q2 net loss widened, driven by impairment chargeCompany received $10 mln upfront payment from Al","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421DL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNMX","LU0889565916.HKD","BK4588","TRDA","PBE","BK4563","LU0882574055.USD","IMRX","LU0320765992.SGD","BK4139","KYMR","ALNY","BK4539","LU0114720955.EUR","TNYA","BK4585","LU0109394709.USD","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657755525","title":"Tenaya Net Loss Widens to $43.39 Million in Q2 FY26; R&D Expenses Slip to $16.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657755525","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657755525?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:44","pubTimestamp":1785962666,"startTime":"0","endTime":"0","summary":"Tenaya net loss widens to $43.39 million in Q2 FY26; R&D expenses slip to $16.6 millionTenaya Therapeutics posted a Q2 net loss of USD 43.4 million, or USD 0.20 a share, widening from USD 23.3 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL8RShts:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","BK4548","LU0314104364.USD","SG9999014021.USD","LU0320765992.SGD","ALNY","LU2210149790.SGD","BK4539","LU0109394709.USD","BK4112","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4139","TNYA","IE00BGHQF748.EUR","NDAQ","LU2210150020.SGD","PBE","LU0882574055.USD","IE00BKPKM429.USD","BCDF","GNMX","SG9999014039.USD","LU0114720955.EUR","SG9999014013.SGD","LU2095319765.USD","BK4588","LU0889565916.HKD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657369525","title":"NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-08-05","url":"https://stock-news.laohu8.com/highlight/detail?id=2657369525","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657369525?lang=en_us&edition=fundamental","pubTime":"2026-08-05 23:01","pubTimestamp":1785942065,"startTime":"0","endTime":"0","summary":"BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2026-08-05Nasdaq 100.NDXTop PerformersPercent ChangeShopify Inc.SHOP.OQ+17.7%Booking Holdings Inc.BKNG.OQ+6.7%Amgen IncAMGN.OQ+5.7%Alnylam Pharmaceuticals, Inc.ALNY.OQ+4.8%Marriott International, Inc.MAR.OQ+4.3%Bottom PerformersPercent ChangeAstera Labs, Inc.ALAB.OQ-10.3%Space Exploration Technologies CorpSPCX.OQ-7.9%Advanced Micro Devices, Inc.AMD.OQ-7.2%Microchip Technology IncMCHP.OQ-4.0%Dexcom IncDXCM.OQ-4.0%The Nasdaq 100.NDXgained 14.23 points, or 0.05%, to 29,747.39 and recorded 6 new highs and no new lows. 45 stocks rose and 58 fell as declining issues outnumbered advancers by about a 1.3-to-1 ratio.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N4422K4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2750360997.AUD","LU0310800379.SGD","LU1803068979.SGD","QQQM","LU2896262040.SGD","LU1323610961.USD","BK4554","LOFF","SHPU","SMH","LU1720051017.SGD","LU2471134879.HKD","LU0786609619.USD","SQQQ","AMGN","LU1023059063.AUD","PBE","LU0109394709.USD","LU0114720955.EUR","LU0353189680.USD","IE00B0T0GQ85.USD","IE00BMPRXQ63.HKD","LU1718418525.SGD","ILDR","SSPC","SHOP","LU0266013472.USD","SMHX","SPCM","07568","LU2750360641.GBP","AMUU","02834","LU1316542783.SGD","BK4614","AMDY","SPAL","BK4543","LU0823434740.USD","AIS","TBXU","TQQQ","LU2097829019.USD","IE00BMPRXR70.SGD","LU1823568750.SGD","IE00BQXX3C00.GBP","IBB","LU0353189763.USD","WSPC","IE00B4R5TH58.HKD","LU1861558580.USD","03455","BK4504","LU0642271901.SGD","LU0708994859.HKD","SPCG","BK4561","SG9999004303.SGD","LU2360107168.USD","LEGR","LU1043141396.HKD","LU0203345920.USD","LU0792757196.USD","BK4528","LU1951198990.SGD","BK4116","BK4573","BK4612","07522","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0251132253.USD","LU1267930573.SGD","SPCF","LU0390134368.USD","BIB","QLD","IE0009355771.USD","BK4082","LU1691799644.USD","NOCT","LU2471134796.USD","LU1232071149.USD","LU2471134952.CNY","CNAV","LU2210150020.SGD","LU2125909247.SGD","QMAR","LU1057294990.SGD","LU2089984988.USD","BK4581","LU2404859741.USD","03034","BK4534","LU0048584097.USD","AIQ","LU1989772923.USD","GB00B4LPDJ14.GBP","LU1623119135.USD","SGXZ23171101.USD","QDEC","COWG","IE00BFTCPJ56.SGD","TQQY","LU1983260115.SGD","XNTK","LU1548497426.USD","LU2456880835.USD","NAPR","WISE","LU1923622614.USD","LU1064131342.USD","LU1852331112.SGD","CHAT","SPAX","IETC","BK4089","LU1121112475.USD","LU1061106388.HKD","BK4575","BKNU","IE00B1BXHZ80.USD","LU0127658192.USD","FTXL","LU0354030511.USD","AMDS","LU2095319765.USD","LU2468319806.SGD","LU1923623000.USD","LU2242649171.HKD","LU2063271972.USD","PSQ","LU2458330243.SGD","IE00BQXX3D17.EUR","LU2125909593.SGD","AMDL","LU0823421333.USD","LU0316494557.USD","IE00BQXX3F31.USD","SPRX","QID","LU0354030438.USD","LU0133085943.USD","SOXX","LU0868494708.USD","LU0174119429.USD","LU1633808545.USD","IE00BD0PCF45.HKD","IE0009356076.USD","LU1880398471.USD","LU2236285917.USD","AMDU","LU2462591350.SGD","LU1951200564.SGD","QQQX","LU2860962120.EUR","LABX","LU1435385759.SGD","BK4613","LU0994945656.USD","LU0082616367.USD","LU1861220033.SGD","LU0979878070.USD","GAMR","BK4599","LU1989772840.SGD","PSI","IE0004445239.USD","LU1989764748.USD","LU2458330169.SGD","LU0345774631.USD","LU0203347892.USD","LU0198837287.USD","QQQA","IE0001KFT4U8.USD","LU2237957902.USD","LU0348723411.USD","AWAY","GPIQ","LU2931357623.SGD","LU2087625088.SGD","BK4512","LU1496350502.SGD","LU0077335932.USD","NDX","LU1242518857.USD","LU0426412945.USD","LU0823434583.USD","07261","MCHP","PJP","SGXZ81514606.USD","LU1861559042.SGD","LU1429558221.USD","IE00BJJMRZ35.SGD","LU2471134523.USD","03086","LU1496350171.SGD","LU0823421416.USD","BBH","AMDG","EKG","LU0109392836.USD","LU2357305700.SGD",".IXIC","BK4551","BK4604","LU0426417589.USD","SPCH","LU0889566641.SGD","AMDD","CHPS","LU0029864427.USD","LU2054465674.USD","SGXZ99366536.SGD","07266","LU1712237335.SGD","DAMD","LU0225283273.USD","LU2404859667.USD","LU0122379950.USD","LU2089985449.USD","LU0882574055.USD","LU0889565833.HKD","LU1699723380.USD","LU0210536198.USD","BK4548","LU2326559502.SGD","MAR","IE00B95QR487.USD","LU2355687059.USD","LU2108987350.USD","NJAN","BK4605","LU1242518931.SGD","ARTY","LU0690374615.EUR","AIPI","SG9999001424.SGD","IBBQ","LU2461242641.AUD","LU2242652126.USD","LU2211815571.USD","LU2361044865.SGD","SOXY","SHPD","LU2237957811.SGD","ALAB","SPCQ","LU0274383776.USD","LU0056508442.USD","LU2361044949.HKD","LU1046421795.USD","BKNG","04332","BK4141","LU1235294995.USD","LU0320765992.SGD","IE00BSNM7G36.USD","ORBX","WNDR","LU1983299246.USD","LU1988902786.USD","LU1303367103.USD","GB00B4QBRK32.GBP","AMDW","SGXZ51526630.SGD","BK4566","SNK","SG9999001440.SGD","LU0823411888.USD","MARS","LU1571399168.USD","LU2417539215.USD","AMYY","BK4139","IE00B5949003.HKD","IE00B5TLWC47.USD","LU0719512351.SGD","WARP","LU0058720904.USD","FAI","QQQ","DXCM","TRFK","IE00BMPRXN33.USD","LU2112291526.USD","BK4532","LU2247934214.USD","TEK","LU0889565916.HKD","NJUL","SPCU","LU2210149790.SGD","LU1861215975.USD","HXC","LU0557290698.USD","LU0128525929.USD","IE00BJT1NW94.SGD","LU2361045086.USD","LU0345774391.USD","IE00B1G9WX41.USD","LU2265009873.SGD","LU2242646821.SGD","LU2098885051.SGD","BK4585","TTEQ","LU2360106780.USD","LU1720051108.HKD","IE00B45NX917.SGD","BK4529","ALNY","LU2250418816.HKD","USXF","IE0002141913.USD","LU0342679015.USD","XSD","LU0690374961.EUR","LU1804176565.USD","AMD","GB00BDT5M118.USD","LU1043141123.HKD","LU0289739699.SGD","SPCX","WUGI","BK4533","HEAL","BK4142","LU2264538146.SGD","BK4524","BAI","LU0868494617.USD","LU2433249047.HKD","LU0081259029.USD","LU0942090050.USD","GNMX","LU2290526834.HKD","BK4588","LU1880398554.USD","LU1267930813.SGD","LU1989764664.SGD","IE00B2B36J28.USD","09086","09834"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656855082","title":"H.C. Wainwright Sticks to Its Buy Rating for Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656855082","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656855082?lang=en_us&edition=fundamental","pubTime":"2026-08-04 23:28","pubTimestamp":1785857334,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma, with a price target of $455.00. Trucch...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656557673","title":"Alnylam Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2656557673","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656557673?lang=en_us&edition=fundamental","pubTime":"2026-08-04 23:04","pubTimestamp":1785855840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656540305","title":"Alnylam Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $455 from $485","url":"https://stock-news.laohu8.com/highlight/detail?id=2656540305","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656540305?lang=en_us&edition=fundamental","pubTime":"2026-08-04 22:18","pubTimestamp":1785853138,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nAZN4TBOJ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","LU0114720955.EUR","ALNY","LU0882574055.USD","BK4548","PBE","GNMX","LU0889565916.HKD","BK4585","BK4588","LU0320765992.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656387125","title":"U.S. Research Roundup-Cloudflare, Replimune, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2656387125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656387125?lang=en_us&edition=fundamental","pubTime":"2026-08-04 15:22","pubTimestamp":1785828137,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Cloudflare, Replimune, WalmartAug 4 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cloudflare, Repl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N4410IM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZO","CBOE","DUOL","CRWV","FICO","EKG","DDOG","WCBR","BLZE","ALHC","NETG","CRWU","SMRF","ARCB","HELX","CRS","FBLG","ITB","DXCM","NET","UPW","IDU","AN","VPU","ALNY","APG","CMG","FTH","ARXS","CLX","CI","CNC","NLR","CEG","IVEP","AEIS","ADPT","BBY","AGCO","EVER","AMRC","DHI","BWXT","ABG","ECHO","FBNC","BOW","LIFE","AVA","BNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100614524","title":"Movement Alert｜Alnylam Pharmaceuticals Rises 5.47% in Regular Trading, Multiple Institutions Call Prior 28% Selloff Overdone","url":"https://stock-news.laohu8.com/highlight/detail?id=1100614524","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100614524?lang=en_us&edition=fundamental","pubTime":"2026-08-03 22:07","pubTimestamp":1785766072,"startTime":"0","endTime":"0","summary":"On August 3, Alnylam Pharmaceuticals rose 5.47% in regular trading, trading at approximately $218.82/share, with turnover of $174 million. The rebound follows a 28%-plus single-day plunge on July 30...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Alnylam Pharmaceuticals Rises; Multiple Institutions Call Prior 28% Selloff Overdone","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656736303","title":"Alnylam Pharmaceuticals is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2656736303","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656736303?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:59","pubTimestamp":1785754740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656327356","title":"Alnylam price target lowered to $450 from $527 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2656327356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656327356?lang=en_us&edition=fundamental","pubTime":"2026-08-03 17:20","pubTimestamp":1785748832,"startTime":"0","endTime":"0","summary":"Barclays analyst Eliana Merle lowered the firm’s price target on Alnylam (ALNY) to $450 from $527 and keeps an Overweight rating on the shares. The...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-450-from-527-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-450-from-527-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","LU0109394709.USD","BK4548","BK4585","BK4139","ALNY","LU0320765992.SGD","LU0882574055.USD","BK4588","PBE","LU0114720955.EUR","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655636030","title":"Alnylam Pharmaceuticals Share Price Weakness Looks 'Overdone' Despite Softer Quarter, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2655636030","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655636030?lang=en_us&edition=fundamental","pubTime":"2026-07-31 23:03","pubTimestamp":1785510196,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals  share price weakness appears overdone despite a softer quarter, with Amvuttra growth and pipeline progress supporting upside, RBC Capital Markets said in a note emailed Friday.The analysts said Amvuttra revenue came in slightly below expectations, and the company lowered its full-year transthyretin revenue guidance after acknowledging that the early stages of the launch benefited from pent-up demand, particularly from patients who had stopped responding to tafamidis.The company reaffirmed its goal of delivering more than 25% total revenue compound annual growth rate through 2030, \"but our read is that the company sounded a bit more measured on that goal as they referred to it as an ambition more than a formal guide,\" the analysts said.The analysts said, overall, the update was disappointing, but the recent share price weakness appears \"overdone.\" The stock now trades at less than 2.5 times guided 2030 revenue, which still offers attractive upside if execution r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALNY","BK4585","GNMX","LU0889565916.HKD","PBE","LU0114720955.EUR","LU0109394709.USD","LU0320765992.SGD","LU0882574055.USD","BK4139","BK4548","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655836995","title":"RBC Cuts Price Target on Alnylam Pharmaceuticals to $350 From $445, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2655836995","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655836995?lang=en_us&edition=fundamental","pubTime":"2026-07-31 20:43","pubTimestamp":1785501781,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (ALNY) has an average rating of overweight and mean price target of $391.83, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic researc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655739365","title":"Analysts Conflicted on These Healthcare Names: Karyopharm Therapeutics (KPTI), Baxter International (BAX) and Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655739365","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655739365?lang=en_us&edition=fundamental","pubTime":"2026-07-31 20:00","pubTimestamp":1785499254,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Karyopharm Therapeutics (KPTI), Baxter Internation...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-karyopharm-therapeutics-kpti-baxter-international-bax-and-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-karyopharm-therapeutics-kpti-baxter-international-bax-and-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0006061336.USD","LU0211327993.USD","BK4588","LU0114720955.EUR","LU0211328371.USD","LU1267930490.SGD","LU0109394709.USD","BK4139","LU0029874061.USD","PBE","LU0889565916.HKD","XLV","BK4504","KPTI","BK4137","LU0320765992.SGD","LU0310799852.SGD","BK4581","BK4548","LU0128526141.USD","BAX","BK4585","ALNY","BK4082","XBI","GNMX","LU0072461881.USD","LU0882574055.USD","LABU","LU1303367103.USD","LU0162691827.USD","HCSG","LU2098885051.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655536579","title":"Alnylam price target lowered to $300 from $400 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2655536579","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655536579?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:56","pubTimestamp":1785498970,"startTime":"0","endTime":"0","summary":"Morgan Stanley lowered the firm’s price target on Alnylam (ALNY) to $300 from $400 and keeps an Equal Weight rating on the shares. Total TTR sales ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-300-from-400-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-300-from-400-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","ALNY","LU0114720955.EUR","LU0109394709.USD","PBE","BK4548","LU0882574055.USD","BK4585","GNMX","LU0320765992.SGD","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655462358","title":"U.S. Research ROUNDUP-Apple, Amazon, Mastercard","url":"https://stock-news.laohu8.com/highlight/detail?id=2655462358","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655462358?lang=en_us&edition=fundamental","pubTime":"2026-07-31 15:13","pubTimestamp":1785482003,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Apple, Amazon, MastercardJuly 31 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including, Apple, Amazon and M","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4N43X0NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VGT","WHD","AGCO","ALAB","LABX","LAZR","AMZN","FDMT","BXMT","COWG","AZYY","AVY","IBAT","AGIO","OWL","SMHX","AR","ALGM","AXSM","BAX","AOS","POW","VT","MACW.SI","ARXS","BLDR","APD","AMP","BDC","AMCX","BHRB","ASH","BIOA","AEP","BELFB","AWK","BMY","BJRI","AAPL","AXTI","BFAM","ALNY","BCYC","BOH","AX","AJG","BSX","GNMX","ALRS","AQMS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":0.0431},{"period":"1month","weight":-0.1809},{"period":"3month","weight":-0.2033},{"period":"6month","weight":-0.2727},{"period":"1year","weight":-0.4835},{"period":"ytd","weight":-0.425}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.028609},{"month":2,"riseRate":0.454545,"avgChangeRate":0.002754},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.012836},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.021744},{"month":5,"riseRate":0.590909,"avgChangeRate":0.038262},{"month":6,"riseRate":0.608696,"avgChangeRate":0.061553},{"month":7,"riseRate":0.652174,"avgChangeRate":0.088481},{"month":8,"riseRate":0.608696,"avgChangeRate":0.040289},{"month":9,"riseRate":0.545455,"avgChangeRate":0.034409},{"month":10,"riseRate":0.409091,"avgChangeRate":-0.042013},{"month":11,"riseRate":0.727273,"avgChangeRate":0.078577},{"month":12,"riseRate":0.454545,"avgChangeRate":0.006257}],"exchange":"NASDAQ","name":"Alnylam Pharmaceuticals","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alnylam Pharmaceuticals,ALNY,Alnylam Pharmaceuticals股票,Alnylam Pharmaceuticals股票老虎,Alnylam Pharmaceuticals股票老虎国际,Alnylam Pharmaceuticals行情,Alnylam Pharmaceuticals股票行情,Alnylam Pharmaceuticals股价,Alnylam Pharmaceuticals股市,Alnylam Pharmaceuticals股票价格,Alnylam Pharmaceuticals股票交易,Alnylam Pharmaceuticals股票购买,Alnylam Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}